The co-silencing of multiple tumor suppressor genes can lead to escalated malignancy in cancer cells. Given the limited efficacy of anticancer therapies targeting single tumor suppressor genes, we developed small circular singlestranded DNA (CSSD) that can up-regulate the expression of co-silenced tumor suppressor genes by sequestering microRNAs (miRNAs) that negatively regulate these genes. We found that cancer patients with low tumor expression of the tumor suppressor genes KLF17, CDH1, and LASS2 had shortened survival times. The up-regulation of these genes upon transfection of artificial CSSD-9 inhibited tumor proliferation and metastasis and promoted apoptosis in vitro as well as in ex vivo and patient-derived xenograft models. In addition, CSSD is more stable and effective than current miRNA inhibitors, and transfecting CSSDs via nanoparticles substantially improved delivery efficiency. The use of a single CSSD can promote the inhibition of multiple tumor suppressor genes. This study provides evidence for the possibility of using CSSDs as therapeutic miRNA inhibitors to target the co-silencing of multiple tumor suppressor genes.
INTRODUCTION
Epigenetic dysregulation and somatic mutations leading to the silenc ing of multiple tumor suppressor genes are prevalent in tumors. Tradi tional antitumor drugs, however, mostly target single oncogenes and not tumor suppressor genes (1) . Thus, nucleic acid-based methods to release the repression of tumor suppressor genes may be of clinical therapeutic significance and may help promote the development of new antitumor drugs.
The dysregulation of microRNAs (miRNAs) has been implicated in tumor malignancy, and each miRNA can have multiple target genes (2, 3) . Therefore, regulating the expression of even a single miRNA to simultaneously release the cosilencing of multiple tumor sup pressor genes may be an effective tumor therapy. To block the func tions of oncogenic miRNAs, approaches based on oligonucleotides, small molecules, and miRNA "sponges" have been developed (4, 5) . However, the tumor suppression efficiency and the duration of these inhibitors need to be improved (4, 6) .
Circular RNAs (circRNAs) are a class of RNAs formed by cova lently closed continuous loops; they can be evolutionarily conserved and more stable than linear RNAs in the cytoplasm (7, 8) . Recently, circRNAs enriched with miRNA binding sites were observed to act as natural miRNA sponges (7, 9) , by which they can regulate gene expression (10, 11) . CircRNA MTO1 was found to act as a sponge of miR9 to suppress hepatocellular carcinoma progression (12) , and silencing of the endogenously occurring RNA circHIPK3 has been shown to inhibit human tumor cell growth by sponging multiple miRNAs (13) . Because circRNAs are not easily degraded, they may absorb miRNAs more effectively than linear miRNA inhibitors. These observations suggested the potential of engineered circular nucleic acids rich in miRNA binding sites to inhibit miRNA function and prevent tumor growth.
Here, by mimicking circRNA characteristics, we designed an ar tificial circular singlestranded DNA (CSSD) molecule containing continuous, multiple miR9 complementary sites that are stable and resistant to degradation. Our results showed that CSSDs effectively released multiple, cosilenced tumor suppressor genes (KLF17, CDH1, and LASS2), upregulating their expression by absorbing oncogenic miRNA9 and consequently suppressing tumor progression and lung metastasis. To improve delivery efficiency, CSSD9 was transfected via nanoparticles. Accordingly, this study may provide stable and effec tive miRNA inhibitors (CSSD) to release cosilenced tumor sup pressor genes for further research and potential clinical application.
RESULTS

Co-silencing of KLF17, CDH1, and LASS2 expression is correlated with escalated tumor malignancy
To examine the effect of tumor suppressor genes on patient survival time in different tumors, we searched the KaplanMeier plotter data base (14) and compared the median survival time linked to 51 tumor suppressor genes in breast, lung, and ovarian cancers by hierarchical cluster analysis (Fig. 1A) . We also analyzed which common tumor suppressor genes' expression was associated with relatively greater median survival time in the three cancers. Of these genes that pos sibly influenced median survival time, five were observed to overlap across the three cancers (Fig. 1B) . Survival curves striated according to expression of either KLF17, CDH1, or LASS2 in breast, lung, and ovarian cancer showed that high expression of any of these tumor suppressor genes associated with longer median survival time ( fig. S1 ). The three genes' expression was positively correlated in breast cancer ( fig. S2 ). We further tested the association between survival time and 1 the expression of the three proteins in hepatocellular carcinoma tissues and found that simultaneous low expression of KLF17, CDH1, and LASS2 was associated with shorter overall survival in hepato cellular carcinoma patients (Fig. 1C) . Moreover, we examined the correlations between KLF17, CDH1, and LASS2 expression and clin ical stage or pathological grade in hepatocellular carcinoma cases. The percentages of clinical stages I and II were 50.8 and 63.9% and those of stages III and IV were 49.2 and 36.1% in groups with low and high expression of the three tumor suppressor genes, respectively (P = 0.029). The percentages of pathological grade III were 23.8 and 7.4% in the low and high expression groups, respectively (P = 0.004) (Fig. 1D) . The percentages of metastasis were 63.3 and 26.7% (P = 0.002) (Fig. 1E) , and the percentages of fetoprotein (AFP) higher than 400 ng/ml were 69.2 and 58.8% in the low and high expression groups, respectively (P = 0.010) (Fig. 1F ). These findings indicated that the cosilencing of KLF17, CDH1, and LASS2 in hepatocellular carcinoma is strongly correlated with poor prognosis, tumor progression, metastasis, and serum AFP content. miR-9 contributes to KLF17, CDH1, and LASS2 co-silencing and malignant tumor progression We studied the effect of releasing the co silencing of KLF17, CDH1, and LASS2 in cancer cells overexpressing these genes upon transfection ( Fig. 2A) . Overexpres sion of the three genes inhibited cell pro liferation (Fig. 2B) , migration (Fig. 2C) , invasion (Fig. 2D) , and colony forma tion (Fig. 2E ) and promoted cell apoptosis (Fig. 2F) . The effect was more evident when the three genes were overexpressed simultaneously than when each gene was overexpressed individually.
Taking into account the efficiency of inhibiting tumor cells with overexpressed KLF17, CDH1, and LASS2, we screened miRNA databases for common carcino genic miRNAs that targeted the three genes and verified the inhibitory effects of these miRNAs on the three target genes by quan titative reverse transcription polymerase chain reaction (qRTPCR) ( fig. S3A ). Fur thermore, we found that 11 miRNA seed sequences shared some sequence simi larity with miR9 (Fig. 3A) . We detected the proliferation inhibition caused by these miRNAs in HeLa cells, and the inhibitory effect of miR9 on proliferation was the most obvious ( fig. S3B ). TCGA (The Cancer Genome Atlas) database query results also support the notion that miR9 expres sion is higher in a variety of tumor tissues than in normal tissues ( fig. S4 ). Bioinfor matics analysis by using miRTarBase (15) , TargetScan (16), or miRanda (17) re vealed that miR9 has highly conserved binding sites on the 3′ untranslated regions (3′UTRs) of KLF17, CDH1, and LASS2 ( fig. S5A ). Furthermore, we found that miR9 suppressed KLF17, CDH1, and LASS2 3′UTR lu ciferase activity ( fig. S5B ) and decreased the expression of KLF17, CDH1, and LASS2 (Fig. 3B) . Thus, the expression of these three genes can be increased by inhibiting miR9.
Nanoparticle-loaded CSSD-9 serves as a miR-9 sponge that increases tumor suppressor gene expression and inhibits tumor malignancy To reduce the miR9 content in tumor cells, we designed several in hibitors based on the sequence of mature miR9. Linear RNA is an oligonucleotide containing one copy of the miR9 binding sites; circR9 and CSSD9s contained two binding sites, and CSSD9 contained four miR9 binding sites (Fig. 3C) . Given that imperfect miRNA bulged sponges are more effective than sponges with a perfect antisense sequence (10, 11, 18) , each miRNA binding site included a bulged , (E) colony formation (scale bars, 2 mm), and (F) apoptosis of HeLa cells transfected with pcDNA3.1-KLF17, pcDNA3.1-CDH1, and pcDNA3.1-LASS2 were measured. FITC, fluorescein isothiocyanate. All data are represented as means ± SEM versus control group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
site. Next, we used exonuclease VII, T5 exonuclease, ribonuclease (RNase) R, medium with serum, or transfection reagent for enzymatic digestion of engineered miRNA sponges. Compared to circR9, CSSD9 was more resistant to enzymatic degradation and more stable in medium with serum or transfection reagent (Fig. 3D) .
Nanoparticle morphology was observed under a scanning elec tron microscope (Fig. 3E ). CSSD9 and other miR9 inhibitors that we designed were transferred into cells on nanoparticles. The effect of CSSD9 on reducing miR9 content and increasing KLF17, CDH1, and LASS2 protein expression was the most obvious (Fig. 3, F and G). We observed the HeLa cell phenotype after CSSD9 treatment using a scanning electron microscope. The cell morphology became spherical from the original spindle shape; cell surface schistose pseudopodia decreased, and apoptotic vesicles appeared (Fig. 3H) . We also assessed the ability of CSSD9 to inhibit tumor cell malignancy and found that CSSD9 inhibited cell proliferation (Fig. 3I) , migration are represented as means ± SEM. *P < 0.05, **P < 0.01, **** P < 0.0001.
( Fig. 3J) , invasion (Fig. 3K) , and colony formation (Fig. 3L ) and promoted cell apoptosis (Fig. 3M ). These effects of CSSD9 on cell proliferation, migration, invasion, colony formation, and apoptosis were dosedependent (0, 0.25, 0.5, and 1 g per 10 5 cells), with a larger effect achieved at higher doses (Fig. 3) .
Whole-genome gene expression chip analysis reveals key biological functions influenced by CSSD-9
To assess the influence of CSSD9 on key biological functions, we analyzed the wholegenome gene expression in HeLa cells treated with CSSD9. Gene expression profiling was conducted to assess the effects of CSSD9 on cancer cells. Bulk RNA was extracted from cells treated with CSSD9, and the expressed transcripts were analyzed by wholegenome gene expression chip (Fig. 4A) . To analyze the ex pression of chemokine and growth factors in the wholegenome gene expression chip data, we optimized the analysis conditions and chose genes that were differentially expressed by more than twofold for gene ontology (GO) analysis. The results showed that after CSSD9 treatment, apoptosis, intracellular pH regulation, immune response, inflammatory response, interleukin18 (IL18)-and IL8-related biological processes, and CCR chemokine receptor binding-related molecular function were all upregulated. By contrast, cell adhesion, invasion, migration, angiogenesis, and positive regulation of IL4 production-related biological processes and growth factor activityrelated molecular function were downregulated (Fig. 4B) . Upregulated genes were associated with inflammatory response, immune response, apoptosis, chemokines, and chemokine receptors ( Fig. 4C ), whereas downregulated genes were associated with migration, invasion, angiogenesis, extracellular matrix, chemokines, chemokine receptors, and growth factor (Fig. 4D) . Furthermore, we analyzed protein protein interactions present among differentially expressed genes (up or downregulated) using the STRING database (19) . Genes up regulated upon CSSD9 treatment were enriched in proteinprotein interactions associated with cell apoptosis and inflammatory response ( Fig. 4E ), whereas downregulated genes were associated with cell invasion, metastasis, and proliferation (Fig. 4F ).
CSSD-9 inhibits tumors in cells expressing miR-9
To examine the sensitivity of other tumor cells to CSSD9, we mea sured miR9 expression ( fig. S6 ) and mRNA expression of KLF17, CDH1, and LASS2 ( fig. S7 ) in various tumor cell types by qRTPCR. We selected HeLa, SiHa, A549, H1299, and HepG2 cells to investigate the inhibitory effect of CSSD9 because these cells had the highest relative expression of miR9 and the lowest relative expression of the target tumor suppressor genes of all the studied cell lines. CSSD9 reduced cell proliferation in all of the cell lines 48 hours after trans fection (Fig. 5A ). CSSD9 overexpression inhibited the metastasis promoting activity of matrix metalloproteinase2 (MMP2) and MMP9 in the cells, as assessed by gelatin zymography (Fig. 5B) . Furthermore, CSSD9 inhibited cell invasion ( Fig. 5C ) and migration ( Fig. 5D ) and promoted apoptosis (Fig. 5E ). In addition, CSSD9 was not toxic to HEK293, LO2, HUVEC, or HaCaT cells ( fig. S8 ). We also de signed other CSSDs that target carcinogenic miRNAs and validated their inhibitory effect in HeLa cells ( fig. S9 ).
To investigate the inhibitory effect of CSSD9 in vivo, about 1 × 10 6 HeLa cells were injected subcutaneously in the middorsal re gion of BALB/c nude mice. When the tumor volume reached 100 to 200 mm 3 , mice were treated with mixed CSSD9 (10 g) and nano particles (10 l) or mixed CSSD9 (20 g) and nanoparticles (20 l)
by intratumoral (I.T.) or intravenous (I.V.) injection every 3 days to ascertain the dose dependency of the effect (Fig. 6A ). Compared with 10g CSSD9 treatment, the administration of 20 g of CSSD9 exhibited more pronounced tumorinhibiting effects. Therefore, we selected a high dose (20 g) of CSSD9 treatment to inhibit tumor detection in vivo. A mixture of 20 g of CSSD9 and 20 l of nano particles was injected into SiHa, A549, and HepG2 tumorbearing mice I.V. or I.T. every 3 days. CSSD9 decreased the tumor growth in these three models, with the inhibitory effect more apparent in I.T. injection groups than in I.V. injection groups (Fig. 6B ). The number of lung metastatic nodules decreased in mice treated with CSSD9 (twotailed unpaired Student's t test or MannWhitney test, P < 0.05) (Fig. 6 , C and D). We also detected miR9 and mRNA expression of KLF17, CDH1, and LASS2 in tumor tissues by qRT PCR. The results showed that CSSD9 suppressed miR9 expres sion ( Fig. 6E ) and increased KLF17, CDH1, and LASS2 expression (Fig. 6F) . KLF17, CDH1, and LASS2 protein expression was also in creased in the CSSD9 treatment group as shown by Western blot analysis (Fig. 6G ). The mRNA expression of some chemokines, chemo kine receptors, and growth factors in tumor tissues was detected by qRTPCR in CSSD9 treatment groups. The mRNA expression variation of CXCR5, IL33, CCL18, FGF11, and VEGFB in tissues was consistent with that of the wholegenome gene expression chip data: The expression of CXCR5 increased, whereas IL33, CCL18, FGF11, and VEGFB decreased in CSSD9-treated tumor tissues (fig. S10).
We next investigated the effect of the nanoparticles delivered with CSSD9 on normal cells in the animal models. We evaluated the com plete blood count, liver function, and kidney function in normal mice (normal group), tumorbearing mice (control group), and mice treated with different doses of I.T. or I.V. injection of CSSD9 (that is, I.T.20 g, I.T.10 g, I.V.20 g, and I.V.10 g groups). Com pared with normal mice, the percentage of neutrophils increased [one way analysis of variance (ANOVA), P < 0.0001], but there was no significant statistical difference between monocytes, lymphocytes, and eosinophils in tumorbearing mice and normal mice. The per centage of basophils was close to 0. After CSSD9 treatment, there was no statistical difference in neutrophils, monocytes, lymphocytes, eosinophils, and basophils ( fig. S11, A and B) . We also performed alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (TBIL), total protein (TP), albumin (ALB), creatinine (CREA), and urea (UREA) tests to eval uate the effect of CSSD9 on liver and kidney functions. Compared with normal mice, the ALT, ALP, TP, and ALB concentrations in tumor bearing mice decreased, whereas the AST and TBIL concentrations increased. After CSSD9 treatment, these indexes reverted to near normal; however, these changes were not statistically significant. In addition, there was no marked difference in CREA and UREA con centrations in all groups ( fig. S11, C and D) . The results showed that CSSD9 exhibits little effect on complete blood count, liver function, and kidney function in mice.
To investigate the in vivo effects of CSSD9 on metastasis, an ex perimental metastasis assay was used to compare lung metastatic and circulating tumor cells (CTCs) in mice injected with A549 cells, stably labeled by green fluorescent protein (GFP). Six weeks after injec tion, mice in the control group showed marked pulmonary metastasis by in vivo fluorescence imaging. The CTCs were analyzed by flow cytometry, and the results showed that CTC was higher in the control group than in the CSSD9 group (Fig. 6H) . The number of lung metastatic 6 of 14 Up-regulated biological processes including immune and inflammatory response and apoptotic signaling pathway are shown in green. Down-regulated biological processes including migration, invasion, proliferation, angiogenesis, and growth factors are shown in red. IB, inhibitor of nuclear factor B; NF-B, nuclear factor B. (C) Up-regulated genes in HeLa cells after CSSD-9 treatment were associated with inflammatory response, immune response, apoptosis, and chemokines/chemokine receptors. (D) Down-regulated genes in HeLa cells after CSSD-9 treatment were associated with migration, invasion, angiogenesis, extracellular matrix, growth factors, and chemokines/chemokine receptors. (E) Inferred up-regulated protein-protein interaction networks based on differentially expressed genes after CSSD-9 treatment were enriched for apoptosis and inflammatory response. (F) Inferred down-regulated protein-protein interaction networks based on differentially expressed genes after CSSD-9 treatment were enriched for invasion, migration, and proliferation.
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nodules decreased in mice treated with CSSD9 (twotailed unpaired Student's t test, P < 0.05) ( fig. S12) .
Furthermore, we examined immune cell development and func tion after CSSD9 transfection in vivo. We evaluated the infiltration of CD8 + T cells and interferon-positive (IFN + ) cells in the tumor tissues after CSSD9 transfection by I.T. or I.V. injection using flow cytometry. The percentages of infiltrating CD8 + T cells and IFN + cells in the tumor tissues increased after CSSD9 treat ment, and the increase in 20g CSSD9 treatment group was more obvious (Fig. 6I) . To detect the reversal of immunosuppression and the target cells besides tumor cells, we measured the percentage of myeloidderived suppressor cells (MDSCs) in tumor, bone marrow, and spleen. The percentage of MDSCs decreased after CSSD9 treat ment (Fig. 6J) .
CSSD-9 specifically inhibits tumors with high miR-9 expression in a patient-derived tumor xenograft model
We obtained 43 different primary tumor fragments (hepatocellular carcinoma, lung cancer, cervical cancer, ovarian cancer, and breast cancer) from 61 patients and established 43 patientderived tumor xenograft (PDX) models, whose clinical and pathological features are shown in Fig. 7A . A schematic of the experiments including treat ment of fresh surgical tumor tissue, passaging in vivo, and I.T. in jection of CSSD9 in the PDX model is shown in Fig. 7B . We detected KLF17, CDH1, LASS2, and miR9 expression in these tumors by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) (Fig. 7C) . Statistical analysis showed that the expression of KLF17, CDH1, and LASS2 was negatively correlated with miR9 in these tumor tissues (Fig. 7D) . To investigate the inhibitory activity 
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of CSSD9 on the growth of patient tumors, mice were implanted with different tumor tissues and assigned to control and CSSD9 groups. We analyzed the relationship between the tumor suppres sor rate of CSSD9 and expression of miR9 and KLF17, CDH1, and LASS2 in patient tumors. The results showed that tumor inhibitory rate was positively correlated with miR9 expression but negatively correlated with KLF17, CDH1, and LASS2 expression (Fig. 7E) . PDX model results suggested a potential clinical therapeutic value of All data are represented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, **** P < 0.0001. CSSD9, which can be viewed as preclinical susceptibility evalua tion before the use of CSSD therapy.
DISCUSSION
Cosilencing multiple oncogenes or releasing the suppression of tumor suppressor genes may have more potential in tumor therapy than traditional targeting antitumor drugs. Here, we analyzed the ex pression of more than 50 tumor suppressor genes and the associated survival time in breast, lung, and ovarian cancers in the KaplanMeier plotter database (14) . The survival time of patients with low tumor expression of KLF17, CDH1, and LASS2 was shorter than that of patients with high expression of these tumor suppressor genes. Sub sequently, the result was verified in hepatocellular carcinoma tissue microarray. In clinical case analysis and cell experiments in vitro, cosilencing of KLF17, CDH1, and LASS2 was related to tumor ma lignancy, and their overexpression inhibited tumor malignancy. Therefore, drugs that improve the expression of these genes may serve as potential antitumor agents. The existing antitumor drugs have difficulty in regulating the expression of multiple genes simul taneously, and excessive inhibition by targeted drugs may also cause side effects, such as nausea, skin ulcers, and abnormal blood pressure. Each miRNA can regulate multiple target genes in different sig naling pathways. Therefore, suppressing miRNAs to temporarily and indirectly regulate multiple tumorrelated genes may be advantageous in cancer therapy. We analyzed a series of common miRNAs targeting KLF17, CDH1, and LASS2, and their seed sequences shared similar sequences with miR9. Therefore, searching for inhibitors of miR9 that enhance the expression of tumor suppressor genes by absorbing miR9 is essential. It was reported that increased miR9 expression predicted worse overall survival and promoted tumor malignancy in various carcinomas (20) (21) (22) (23) (24) . The current miRNA inhibitors, ex pression vectors, and chemically modified antisense oligonucleotides may provide a transient depression of miRNAs in cells (4), or the effective dose in vivo is high (6) .
Here, CSSD9 was designed as a miR9 sponge mimicking circRNA. A large number of binding sites increase the likelihood of reaching maximal miRNA sequestration; however, such a number may also increase the formation of secondary structures (18) . Taking this into account, we designed four miRNA binding sites in each CSSD9, with each binding site including a bulged site. The imperfect miRNA sponges were attributed to the impediment of quick turnover of the sponge by endonucleolytic cleavage, which prolonged the seques tering effects of the miRNA (25, 26) . The results showed that CSSD9 was more efficient and stable than other linear or cyclic miRNA sponges. In tumor cells, CSSD9 still produced a stable inhibitory effect on miR9 that lasted up to 96 hours. This finding suggested that the clinical application of CSSD will reduce the frequency of medications and increase persistence and effectiveness.
In vitro experiments showed that CSSD9 transfected in cells com petitively bound and inhibited miR9 activity, thereby increasing the expression of miR9-targeted tumor suppressor genes-KLF17, CDH1, and LASS2-in cancer. KLF17, CDH1, and LASS2 were correlated with tumor malignancy and apoptosis through the regulation of essential signaling pathways (27) (28) (29) . CSSD9-induced KLF17 over expression decreased cancer metastasis by downregulating the in hibition of DNA binding 1 to promote Ecadherin expression, which inhibits tumor migration and invasion through epithelialmesenchymal transition-associated processes (27, 30, 31) . CSSD9 also directly ab sorbed miR9, which maintained the levels of Ecadherin by pro longing the halflife of targeted mRNA (28) . In addition, it enhanced the expression of miR9 target gene LASS2 (also called tumor me tastasis suppressor gene 1), which can inhibit Bcl2 and survivin ex pression (29, 32) to promote apoptosis and decrease MMP2 and MMP9 activities to inhibit epithelialmesenchymal transition (33) . Whole genome gene expression chip analysis was conducted to assess the effects of CSSD9 on cancer cells. The differentially expressed genes were subjected to GO analysis. The results showed that after CSSD9 treatment, cell adhesion, invasion, migration, and angiogenesis related biological processes were downregulated, whereas apoptosis related biological processes were upregulated. CSSD9 was found to enhance immune and inflammatory responses. It was reported that exogenous circRNA can induce cellular immune response (34), so we detected the infiltration of CD8 + T cells in tumor tissues and MDSCs in tumor, bone marrow, and spleen after CSSD9 treatment. CSSD9 increased infiltration of CD8 + T cells and IFN + cell per centages in the tumor tissues and inhibited the MDSCs. This indi cated that CSSD9 also increased the immune response in vivo to inhibit tumors.
In the miRNA database (15) , the miR9 sequences between humans and mice showed no difference. Therefore, the efficacy and toxicity of CSSDs in the mouse models were markedly close to those in human experiments. In vivo experiments demonstrated that CSSD9 inhibited tumor growth and pulmonary metastasis. The results of the PDX model showed that CSSD9 was highly selective for tumors with high miR9 levels. In addition, CSSD9s were transfected into cells or in fected into tumors by special nanoparticles. The nanoparticles were spherical and uniform in size, and the average size was 80 to 100 nm. Displaying large specific surface areas, they were characterized by surface and smallsize effects. They can bind to nucleic acids stably and protect the nucleic acids from degradation by nucleases. Given the special structures of the nanoparticles, we transfected CSSD9 into tumor cells by the nucleic acid-nanoparticle complex efficiently. In addition, cytotoxicity was considerably low. In vivo, there was no obvious effect on complete blood count, liver function, or kidney function after CSSD9 treatment. Moreover, we designed other CSSDs that targeted carcinogenic miRNAs and had a substantial inhibitory effect on tumor cells.
In summary, our study indicated that CSSD9 transfected into cells on nanoparticles effectively inhibited the proliferation, migration, and invasion and promoted the apoptosis of multiple tumors. CSSD9 acted as a sponge and directly inhibited miR9 activity, thereby re storing the functions of miR9 target tumor suppressor genes KLF17, CDH1, and LASS2 in tumor cells. The schematic diagram of the proposed mechanisms underlying antitumor of CSSD is shown in fig. S13 . We found that CSSD9 targeted not only tumor cells but also MDSCs. Further research is needed to determine how CSSD9 may affect tumor immunity. Although CSSD9 can stably inhibit the expression of miR9 for more than 72 hours, further improvement in its stability should be able to enhance its tumor inhibitory effect. The introduction of chemically modified or highly stable nucleic acid structures may possibly help achieve this. In addition, we can im prove the CSSD adsorption efficiency by designing different se quences or considering the seed sequence of multiple miRNAs. The efficiency of CSSD administration via nanoparticles should also be further optimized, and the carrier could be further modified to aid CSSD visualization in the tumor. These findings revealed a miRNA inhibitor, namely, our artificial CSSD, which effectively decreased tumor promoting miRNA activities by transfecting nanoparticles in vitro and in vivo. This study provides new insights into the miRNA based resurrection of "cosilenced" tumor suppressor genes and re ports a precise multitarget drug for potential tumor therapy.
MATERIALS AND METHODS
Study design
This study aimed to demonstrate that cosilenced tumor suppressor genes can be reactivated by nanoparticleloaded CSSDs, which ab sorb miRNAs to suppress tumor malignancy. We first analyzed the effect of 51 tumor suppressor genes on the median survival time of breast, lung, and ovarian cancers and screened three common tumor suppressor genes, namely, KLF17, CDH1, and LASS2, whose associa tions with the median survival time in cancers were relatively greater than others. Hepatocellular carcinoma pathological analysis also dem onstrated that cosilencing of KLF17, CDH1, and LASS2 is correlated with escalated malignancy.
Because miR9 contributed to KLF17, CDH1, and LASS2 co silencing, we designed CSSD9 containing miR9 binding sites to up regulate the expression of cosilenced tumor suppressor genes by absorbing miR9. Nanoparticleloaded CSSD9 served as a miR9 sponge that inhibited multiple tumor malignancy by increasing tumor suppressor gene expression in vitro and in vivo in a dosedependent manner. Wholegenome gene expression chip analysis revealed key biological processes and molecular functions influenced by CSSD9. Primary tumor fragments (hepatocellular carcinoma, lung cancer, cervical cancer, ovarian cancer, and breast cancer) were collected from 61 patients to construct 43 PDX models to test whether CSSD9 was more effective in inhibiting tumors that have high miR9 ex pression. Details on sampling and experimental replicates are pro vided in each figure legend. All treatments were randomly allocated, and all analyses were done by investigators who were blinded to the treatment allocation.
CSSD design
Two singlestranded DNAs (ssDNAs) contained two miRNA binding sites linked by oligo(dT) (table S1). Each miRNA binding site included a bulged site. The ends of the two ssDNAs were complementary sequences. They were combined in annealing buffer (Beyotime Biotechnology), heated for 2 min at 95°C, and allowed to cool at room temperature and form circular DNA. After exonuclease VII (New England Biolabs) treat ment, the ssDNAs without cyclization were removed, and the CSSDs were purified.
Cell culture and transfections
Cells were obtained from the American Type Culture Collection and KeyGEN. HeLa, SiHa, HepG2, HEK293, and HaCaT were cultured in Dulbecco's modified Eagle's medium. A549, H1299, SMMC7721, PLCPRF5, Bel7402, MCF7, MX1, and LO2 were cultured in RPMI 1640 medium. SKOV3 was cultured in McCoy's 5A medium (modified), and HUVECs were cultured in endothelial cell medium. The medium was supplemented with 10% fetal bovine serum (FBS) and 1% penicillinstreptomycin solution at 37°C in 5% CO 2 . All CSSDs, miRNA mimics, inhibitors, scramble controls, and pcDNA3.1KLF17, pcDNA3.1CDH1, and pcDNA3.1LASS2 were transfected into cells by nanoparticles (Nantong Micropoly Bio Technologies Ltd.), a trans fection reagent based on nanogene transfer technology. The nano particles adsorb nucleic acids on their surfaces by electrostatic adsorption. Even smallvolume particles can have a large effective surface area, which can be combined with nucleic acid. The nano particles help protect the nucleic acids, circumventing their degrada tion and destruction by nucleases. Primers used are shown in table S2.
Online prediction of target genes
The following bioinformatics software was used: miRTarBase (http:// mirtarbase.mbc.nctu.edu.tw/) (15), TargetScan (http://targetscan.org) (16), miRanda (https://omictools.com/mirandatool) (17) , and CircNet (http://circnet.mbc.nctu.edu.tw/) (35) . MiRTarBase is a comprehen sive, ex perimentally validated miRNAtarget interactions database. TargetScan and miRanda predict biological targets of miRNAs. miRNAs targeting KLF17, CDH1, and LASS2 included both experimentally val idated and predicted data.
Kaplan-Meier plotter
The KaplanMeier plotter database (http://kmplot.com) (14) was used to analyze the median survival time and survival curve of tumor suppressor genes in breast, lung, and ovarian cancers. The patient samples selected were divided into two cohorts according to high and low expression of KLF17, CDH1, and LASS2 by autoselecting the best cutoff, whereby the lower and upper quartiles are computed, and the best performing threshold was used as a cutoff. Breast cancer data from all versions of the database were used, and in lung and ovarian cancers, the current version of the database was used for analysis. For array quality control, we excluded biased or outlier arrays.
Gelatin zymography
MMP activity was measured by gelatin zymography using precast zymogram gelatin gels (10% polyacrylamide containing 0.1% gelatin; Novex/Invitrogen Corp.) following the manufacturer's instructions. The enzyme sample (15 g of protein) was denatured in SDS buffer (without reducing conditions) using trisglycineSDS sample buffer (Novex/Invitrogen Corp.). After electrophoresis, the gel was rinsed overnight and incubated at 37°C for 20 hours to allow gelatinolytic activity. The gel was stained with Coomassie Brilliant Blue. MMP activity was detected as unstained bands against the background of bluestained gelatin (36) .
Scanning electron microscope
The CSSD9 and nanoparticles (Nantong Micropoly Bio Technologies Ltd.) were mixed for 15 min at room temperature according to the manufacturer's instructions and then added dropwise into HeLa cells. After 48 hours, cells were fixed in 2.5% glutaraldehyde at 4°C for 4 hours and 1% osmic acid at 4°C for 1 hour, then dehydrated in acetone/isoamyl acetate (1:1) for 10 min and isoamyl acetate for 30 min, and dried with acetonitrile for 15 to 20 min for each concentration. After vacuum freezedrying and coating with gold, cells were photo graphed using a scanning electron microscope (JEOL6000). At 12, 24, 36, 48, 60 , and 72 hours after transfection, cell culture medium was removed and 100 l of methylthiazolyldiphenyltetrazolium bromide (MTT) (1 mg/ml) was added to each well of a 96well plate. Afterward, the cells were incubated for 5 hours at 37°C in 5% CO 2 . The MTT solution was discarded, and 100 l of dimethyl sulfoxide was added to each well. Absorbance was measured at a wavelength of 490 nm using an ELISA microplate reader (BioRad). Assays were repeated at least three times.
Cell proliferation assay
Cell migration assays
For woundhealing assays, cells were plated into 24well culture plates until a monolayer was formed. A straight scratch was created in the center of each well using a micropipette tip. Cell migration was assessed by measuring the movement of the cells into the scratch in the well. The distance of wound closure at 24 and 48 hours was mea sured and normalized by wound length at 0 hours. Each experiment was performed in triplicate.
Cell invasion assays
Cells in serumfree medium were seeded onto a chamber coated with Matrigel (BD Biosciences) and inserted in a well of a 24well plate. Medium with 10% FBS was added to the well below the chamber as a chemoattractant. After 24 hours, invasive cells located on the lower surface of the chamber were stained with 0.1% crystal violet and counted.
Cell apoptosis
Cells were transfected with CSSDs. After 48 hours, they were har vested with 0.25% trypsin without EDTA. They were also washed twice with icecold phosphatebuffered saline (PBS), resuspended in 250 l of binding buffer, adjusted to 1 × 10 6 /ml, and fixed in 1% parafor maldehyde. Subsequently, they were stained with the Annexin V/PI Apoptosis Detection Kit (KeyGen Biotech). They were analyzed with a flow cytometer (Millipore) after incubation in the dark for 30 min.
Colony formation assay
Cells were transfected with KLF17, CDH1, LASS2, or CSSDs for 48 hours. Subsequently, they were seeded into sixwell plates (800 cells per well) and incubated for 14 days. The plates were washed with PBS and stained with 0.1% crystal violet for 15 min at room tem perature. The number of colonies with more than 50 cells was man ually counted under a microscope.
Whole-genome gene expression chip analysis
HeLa cells were treated with CSSD9 for 48 hours. The cells were lysed to isolate RNA, and gene expression was detected with whole genome gene expression chip (Genergy). Data analysis was per formed to reveal critical pathways. GO analysis (DAVID; https:// david.ncifcrf.gov/) (37) was used to detect changes in molecular functions, biological processes, and cellular components induced by CSSD9. The STRING database (https://stringdb.org) (38) was used to analyze proteinprotein interactions. On day 27, the mice were sacrificed. Tumor tissues and lung tissues were collected, fixed with 10% formalin, and em bedded in paraffin, followed by H&E or IHC staining. The remain ing tissues were kept in a deep freezer at −80°C for isolating protein and RNA. The blood routine index of mice was detected by auto matic blood analyzer (SYSMEX XT2000i), and the full automatic biochemical analyzer (Hitachi 7020) was used for the analysis of liver and kidney function (LEADMAN).
Xenograft tumor model
Experimental metastasis assay A549GFP cells (2 × 10 5 ), which were stably labeled by GFP, were in jected I.V. through the tail vein of BALB/c nude mice (4 to 6 weeks old). The CSSD9 group was treated every 3 days with I.V. CSSD9 (20 g) in nanoparticles (20 l) after cell injection. After 6 weeks, peripheral blood (500 to 700 l) was collected from the inferior vena cava of each animal under anesthesia (2% pentobarbital, 40 to 50 mg/kg, intraperitoneal injection). Whole blood was processed within 1 hour of collection to lyse red blood cells with Red Blood Cell Lysis Buffer (Beyotime Biotechnology), and GFPpositive mononuclear cells in peripheral blood samples were detected by flow cytometry (39) .
PDX models
Fortythree fresh surgical tumor tissues (F0, hepatocellular carcinoma, lung cancer, cervical cancer, ovarian cancer, and breast cancer) were collected immediately after surgery without any other treatment from 61 patients in S. G. Hospital (Shandong, China), Tianjin Medical University General Hospital, and the Hospital of Shunyi District, Beijing. A written informed consent was obtained from each patient. According to the Declaration of Helsinki, studies were performed after approval of the ethics committee of Nankai University, including the use of animal experiments and tumor specimens. The tumors were divided into three parts. One part was fixed for detection of KLF17, CDH1, and LASS2 expression in IHC. Another part was used for the detection of miR9 expression in quantitative realtime PCR, and the remaining fresh tumor tissues were cut into 1 to 2mm 3 pieces in antibiotic-RPMI 1640 medium containing penicillin (100 U/ml) and streptomycin (0.1 mg/ml). Tumor fragments were implanted sub cutaneously into the right axilla of 4 to 6weekold BALB/c nude mice. By palpation of the skin at the tumor site, we selected mice that bore tumor nodules and began to measure the tumor volumes. When the tumor size reached 100 to 200 mm 3 , the samples (F1) were divided into pieces for in vivo passaging to construct F2 and then F3 tumors as described above. These transplanted tumors were ana lyzed by pathology, and the results were consistent with the clinical pathological analysis (40) . When the F3 tumor size reached 100 to 200 mm 3 , the mice bearing different tumor types were randomly divided into control and CSSD groups consisting of four mice per group. Twenty micrograms of CSSD9 with 20 l of nanoparticles was I.T. administered in mice in the CSSD9 group every 3 days for 18 days. The tumor inhibitory rate of CSSD9 was calculated using the following formula: Inhibition rate = (tumor volume control − tumor volume CSSD )/tumor volume control .
Quantitative real-time PCR Total RNA was extracted from cells using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Afterward, comple mentary DNAs were synthesized from total RNA using the PrimeScript RT Reagent Kit (Tiangen). U6 was used as an internal control. All primers were synthesized by Invitrogen. The primers used in qPCR are shown in table S3. All results are expressed as the means ± SD of three independent experiments.
Western blot analysis
Collected tumor tissues were lysed in a buffer containing Hepes (25 mM; pH 7.5), NaCl (150 mM), 1% Triton X100, 10% glycerol, EDTA (5 mM), and a protease inhibitor cocktail. Protein concentration was determined using bicinchoninic acid assay. Cells were washed with PBS and lysed in icecold lysis buffer with protease inhibitor cock tail (Sigma) for 30 min. Lysates were separated by electrophoresis and transferred on polyvinylidene difluoride membranes (Millipore). The membranes were blocked and incubated with primary antibody of KLF17 (1:500 dilution; Santa Cruz Biotechnology), CDH1 (1:500 dilution; Abcam), and LASS2 (1:500 dilution; Santa Cruz Biotechnology). Subse quently, they were incubated with a goat antirabbit immunoglobulin G-horseradish peroxidase (HRP) secondary antibody (Thermo Fisher Scientific). GAPDH (glyceraldehyde3phosphate dehydrogenase) was used as loading control. Protein expression was assessed by enhanced chemiluminescence substrate (Millipore) and exposed to the chemi luminescence film.
IHC assay and analysis
The hepatocellular carcinoma tissue microarrays containing 171 cases were purchased from US Biomax for IHC, followed by analysis of correlation between survival time, clinical stage, pathological grade, metastasis, AFP content, and KLF17, CDH1, and LASS2 expression. The tissues were incubated with xylene for deparaffinization and decreasing concentrations of ethanol for rehydration. Next, 3% hydrogen peroxide was applied to block endogenous peroxidase ac tivity. Antigen retrieval was performed by boiling the slides in citrate buffer (10 mM; pH 6.0) in microwave (Midea) and keeping the temperature between 92° and −98°C for 20 min (41). After block ing, the samples were incubated with primary antibodies overnight at 4°C: Mouse polyclonal antiKLF17 (1:200 dilution; Santa Cruz Biotechnology), mouse polyclonal antiLASS2 (1:200 dilution; Santa Cruz Biotechnology), rabbit polyclonal antiCDH1 (1:100 dilution; Abcam), and PBS were used as negative control. The secondary an tibody was added using the HRPPolymer AntiMouse/Rabbit IHC Kit (Maixin Biotech) for 1 hour at room temperature. Subsequently, samples were developed with diaminobenzidine reagent, counter stained with hematoxylin, and mounted with Permount. IHC score was calculated by multiplying the intensity (0, negative; 1, canary yellow colors; 2, claybank; 3, brown) and percentage of cells with positive scores (1, less than 25%; 2, 25 to 50%; 3, 51 to 75%; 4, more than 75%).
Fluorescence in situ hybridization
FAMlabeled locked nucleic acid-modified oligonucleotide probes complementary to mature miR9 were purchased from GenePharma. The probe sequences were as follows: 5′TCATACAGCTAGATA ACCAAAGA3′. After deparaffinization and deproteinization, the slides were prehybridized with 1× hybridization buffer without probes. The hybridization was carried out overnight in a 1× hybrid ization buffer (30 to 70 l) with predenatured miRNA probes. After washing, the slides were stained with 4′,6diamidino2phenylindole (DAPI) and analyzed by confocal laser scanning microscopy.
Statistical analysis
The significance of the overlap between the tumor suppressor genes associated with median survival time represented in Venn diagrams was calculated using a hypergeometric distribution test. When nor mality assumptions were met, twotailed unpaired Student's t test was used for comparing two groups of data. For paired observations and repeated measures over time, we used Wilcoxon matchedpairs signedrank test and twoway ANOVA with Bonferroni's multiple comparison posttest or oneway ANOVA analysis. When normality assumptions were not met (KolmogorovSmirnov test, P < 0.05), non parametric statistical tests were performed. MannWhitney or Kruskal Wallis test with Dunn's multiple comparison post hoc test was performed in the comparison of two or more groups. For survival studies, Kaplan Meier was used to analyze the survival time comparing two and three groups. Pearson's correlation was used to measure the linear correlation for two random variables. Values are expressed as means ± SEM unless otherwise indicated, and P < 0.05 was deemed significant.
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